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Prokaryotes have developed an adaptive immune system called Clustered regularly
interspaced short palindromic repeats (CRISPR) to combat attacks by foreign mobile genetic
elements (MGEs) such as plasmids and phages. In the past decade, the widely characterized
CRISPR-Cas9 enzyme has been redesigned to trigger a genome editing revolution. Class II
type V CRISPR-Cas12a is a new RNA guided endonuclease that has been recently harnessed
as an alternative genome editing tool, which is emerging as a powerful molecular scissor to
consider in the genome editing application landscape. In this review, we aim to provide a
mechanistic insight into the working mechanism of Cas12a, comparing it with Cas9, and
eventually provide an overview of its current applications in genome editing and
biotechnology applications.Genome editing is a type of genetic engineering where a DNA
is inserted, deleted or replaced in the genome of a living or-
ganism. The application of this technology has revolutionized
various research areas ranging from biomedicine to biotech-
nology or synthetic biology [1e3]. A key point to initiate the
editing is the need to generate a double strand break (DSB) in
the DNA at a specific locus in the genome. To achieve this
precise DSB researchers have developed engineeredBiology Group, Novo Nor
Blegdamsvej 3-B, Copen
u.dk (G. Montoya).
g Gung University.
ublishing services by Else
/by-nc-nd/4.0/).nucleases, also termed “molecular scissors”. Previous efforts
have focused in the molecular understanding and redesign of
different protein templates, such as homing endonucleases,
zinc finger nucleases (ZFN) and TALEN. These tools have
shown their utility in different genome editing applications
[4e6] including the correction of mutations involving mono-
genic diseases [7,8]. However, the engineering of new DNA
specificities in these protein scaffolds is cumbersome.disk Foundation Centre for Protein Research, Faculty of Health and
hagen 2200, Denmark.
vier B.V. This is an open access article under the CC BY-NC-ND
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tems (Clustered Regularly Interspaced Short Palindromic
Repeats-CRISPR associated proteins) as molecular scissors,
where a simple exchange of the RNA guide sequence is
enough to redesign the nuclease specificity has paved the way
for a revolution in the life sciences [9e11].
CRISPR repeats are associated with Cas proteins consti-
tuting an adaptive immune system in bacteria and archaea
protecting them from foreign mobile genetic elements [12].
The discovery of CRISPR-Cas revealed the capability of bac-
teria and archaea to acquire and integrate genetic elements
into its own genome, demonstrating the exchange of infor-
mation between the environment and prokaryotic genomes
[12]. The genetic record of previous attacks by foreign nucleic
acids is stored in the CRISPR arrays. These arrays are made of
short and conserved repetitive sequences called repeats
which are strategically placed between unique sequences
called spacers. They are inserted by specialized Cas proteins
into the CRISPR array during infections by invading nucleic
acids [13e16]. The adaptive immunity by prokaryotes against
foreign MGEs is achieved through the formation of RNA-
guided endonucleases, which constitute the effector
complexes and are able to detect secondary infection by a
foreign DNA that was previously incorporated into the CRISPR
array [10].
The CRISPR-Cas systems are classified into two classes
(Classes 1 and 2) that are subdivided into six types (types I
through VI). Class 1 (types I, III and IV) systems use multiple
Cas proteins in their CRISPR ribonucleoprotein effector nu-
cleases and Class 2 systems (types II, V and VI) use a single Cas
protein [17]. Class 1 CRISPR-Cas systems are most commonly
found in bacteria and archaea, and comprise ~90% of all
identified CRISPR-Cas loci. The Class 2 CRISPR-Cas systems,
comprising the remaining ~10%, exists almost exclusively in
bacteria [18], and assemble a ribonucleoprotein complex,
consisting of a CRISPR RNA (crRNA) and a Cas protein [10]. The
crRNA contains information to target a specific DNA sequence
[19]. These multidomain effector proteins achieve interfer-
ence by complementarity between the crRNA and the target
sequence after recognition of the PAM (Protospacer Adjacent
Motif) sequence, which is adjacent to the target DNA [20].
These ribonucleoprotein complexes have been redesigned for
precise genome editing by providing a crRNA with a rede-
signed guide sequence, which is complementary to the
sequence of the targeted DNA [21,22]. The most widely char-
acterised CRISPR-Cas system is the type II subtype II-A that is
found in Streptococcus pyogenes (Sp), which uses the protein
SpCas9, Cas9 was the first Cas-protein engineered for use in
gene editing [9]. Class 2 type V is further classified into 4
subtypes (V-A, VeB, VeC, VeU). At present, VeC and VeU
remain widely uncharacterised and no structural informa-
tion on these systems is available [23]. V-A encodes the pro-
tein Cas12a (also known as Cpf1) and recently several high
resolution structures of Cas12a have provided an insight into
its working mechanism [24e26].
This system, involving RNA-guided interference, has been
harnessed into a versatile biotechnological tool for genome
editing [9e11], whereby a simple exchange of the RNA guide
sequence can be employed to re-engineer nuclease specificity,
leading to a revolution in the life sciences. Cas9, belonging toClass 2 Type II CRISPR-Cas interference system, is the more
extensively used tool for genome editing. However, the over-
whelming efficiency in genome sequencing of different or-
ganisms has generated a large amount of data helping the
identification of new systems whose use in genome editing is
currently being explored. Among them there are new mem-
bers of Class 2, such as Cas12a [18,23,27].
CRISPR-Cas immunity involves three major sequential
steps: adaptation, expression/maturation and interference
(Fig. 1), each step needs specific Cas proteins encoded by the
cas genes near the CRISPR array, together with other
accessory proteins [2,28,29]. The CRISPR-Cas adaptation
stage involves the identification and extraction of the pro-
tospacer from the invading DNA/RNA and its subsequent
incorporation into the CRISPR array. Both these functions
are performed by the versatile Cas1-Cas2 adaptation com-
plex. The identification of the protospacer starts with the
recognition of the PAM by the adaptation complex [28],
subsequently the spacer (sequence adjacent to the PAM) is
integrated into the CRISPR array and the conserved repeat
sequence is duplicated. The PAM sequence is excluded from
the CRISPR array and is one of the first recognition motifs
used for identifying target nucleic acids for degradation
[16,24,28]. During the expression/maturation stage, the
CRISPR array is transcribed into a long pre-CRISPR RNA (pre-
crRNA) molecule. The pre-crRNA is processed into shorter
crRNA molecules each containing a spacer and a part of the
repeat sequence. Finally, interference can occur, after the
crRNA forms a complex with the effector protein, forming a
functional RNA guided endonuclease. This endonuclease is
guided by the crRNA, which after PAM recognition hybrid-
izes with the target DNA through its spacer sequence, and
eventually, cuts the target DNA sequence. In this review, we
describe the structural and functional features of Cas12a, a
cousin of Cas9 belonging to the Class 2 Type V CRISPR-Cas
system, which has been repurposed into an alternative
and promising gene editing tool based on its substantial
differences with Cas9 [17,30].Cas12a crRNA biogenesis
RNA sequencing of small RNA molecules extracted from
Francisella novicida U112 culture containing Cas12a-based
CRISPR loci revealed that mature crRNAs for Cas12a are
42e44 nt in length, with the first 19/20 nt corresponding to
the repeat sequence and the remaining 23-25 nt to the
spacer sequence [31]. In type II CRISPR systems, the matu-
ration of crRNA is done by host housekeeping protein
RNase III together with the trans-activating crRNA
(tracrRNA), which is base paired with the pre-crRNA, in
presence of Cas9 [32,33]. In contrast, it has been shown that
Cas12a processes its own pre-crRNA into mature crRNAs,
without the requirement of a tracrRNA, making it a unique
effector protein with both endoribonuclease and endonu-
clease activities [34].After the pre-crRNA has been tran-
scribed during the expression stage, Cas12a cuts it 4 nt
upstream of the hairpin structures formed by the CRISPR
repeats, producing intermediate crRNA molecules which
undergo further processing in vivo into mature crRNAs.
1. Adaptation
Cas12a Cas4 Cas1 Cas2
Pre-crRNA
2. Expression
CRISPR array
CRISPR locus
Transcription of CRISPR locus
Pre-crRNA
Cas12a processes its own pre-crRNA3. Maturation
Formation of surveillance molecules
Cas12a
Interference complex cleaves phage DNA
4. Interference
Fig. 1 Stages of CRISPR-Cas immunity- Adaptation, Expression/Maturation, Interference.
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ribonucleoprotein complex assembly
Type II (Cas9) and type V (Cas12a) CRISPR-Cas systems
possess a characteristic Ruv-C like nuclease domain (Fig. 2A),
which has been shown to be related to IS605 family trans-
poson encoded TnpB proteins [18]. Crystallographic and
cryo-EM data [24,31,35,36] reveal that Cas12a adopts a
bilobed structure formed by the REC and Nuc lobes (Fig. 2B).
The REC lobe is comprised of REC1 and REC2 domains, and
the Nuc lobe is comprised of the RuvC, the PAM-interacting
(PI) and the WED domains, and additionally, the bridge
helix (BH). The RuvC endonuclease domain of this effectorprotein is made up of three discontinuous parts (RuvC I-III).
The RNase site for processing its own crRNA is situated in
the WED-III subdomain, and the DNase site is located in the
interface between the RuvC and the Nuc domains. These
structural studies have also shown that the only the 5’
repeat region of the crRNA is involved in the assembly of the
binary complex. The 19/20 nt repeat region forms a pseu-
doknot structure through intramolecular base pairing. The
crRNA is stabilized through interactions with the WED, RuvC
and REC2 domains of the endonuclease, as well as two hy-
drated Mg2þ ions [24e26,35]. This binary interference com-
plex is then responsible for recognizing and degrading
foreign DNA.
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Fig. 2 Domain organisation and R-loop complex of Ca9 and Cas12a.
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PAM recognition is a critical initial step in identifying a pro-
spective DNA molecule for degradation since the PAM allows
the CRISPR-Cas systems to distinguish their own genomic
DNA from invading nucleic acids [37]. Cas12a employs a
multistep quality control mechanism to ensure the accurate
and precise recognition of target spacer sequences. The WED
II-III, REC1 and PAM-interacting domains are responsible for
PAM recognition and for initiating the hybridization of the
DNA target with the crRNA. After recognition of the dsDNA by
WED and REC1 domains, the conserved loop-lysine helix-loop
(LKL) region in the PI domain, containing three conserved ly-
sines (K667, K671, K677 in FnCas12a), inserts the helix into the
PAM duplex with assistance from two conserved prolines in
the LKL region. Structural studies show the helix is inserted at
an angle of 45 with respect to the dsDNA longitudinal axis,
promoting the unwinding of the helical dsDNA. The critical
positioning of the three conserved lysines on the dsDNA ini-
tiates the uncoupling of the WatsoneCrick interaction be-
tween the base pairs of the dsDNA after the PAM. The target
dsDNA unzipping allows the hybridization of the crRNA with
the strand containing the PAM, the ‘target strand (TS), while
the uncoupled DNA strand, non-target strand (NTS), is con-
ducted towards the DNase site by the PAM-interacting domain
[24,26,35]. Cas12a has been shown to efficiently target spacer
sequences following 5’T-rich PAM sequence. The PAM for
LbCas12a and AsCas12a has a sequence of 50-TTTN-3' and forFnCas12a a sequence of 50-TTN-30 and is situated upstream of
the 5'end of the non-target strand [26,31,34]. It has also been
shown that in addition to the canonical 50-TTTN-30 PAM,
Cas12a also exhibits relaxed PAM recognition for suboptimal
C-containing PAM sequences by forming altered interactions
with the targeted DNA duplex [38].DNA unzipping, propagation and cleavage
Once the crRNA-DNA hybrid R-loop starts forming, the
enzyme then looks for a seed sequence of 3-5 nt on the PAM
proximal end, the next check point in the correct identifi-
cation of the target (Fig. 3). It has been reported that mis-
matches in the seed sequence results in the loss of cleavage
activity [31,34]. Presence of the seed sequences promotes
further hybridization of the crRNA-target DNA. Structural
studies have shown that TS and NTS follow different path-
ways to the nuclease site [24], with several residues in the PI
domain undergoing conformational changes and adopting a
‘rail’ shape to accommodate the nt-strand and eventually
guiding it to the catalytic site. This structure also shows the
presence of a barrier, the septum, to prevent the re-
annealing of the dsDNA.
A recent cryo-EM analysis on the intermediate catalysis
products of Cas12a [36] revealed that the enzyme utilizes a
further three-checkpoint control to sense the hybridization
between the crRNA and the DNA. Three regions within the
enzyme, the ‘REC linker’, the ‘lid’ and the ‘REC finger’
Cas12a
precr-RNA
processing
crRNA
Cas12a-crRNA
PAM scanning
PAM
seed sequence
 scanning and crRNA-DNA
hybridization
PAM
Checkpoints
REC linker 
Lid
REC finger
PAM
Catalysis
PAM distal product 
released
PAM
unspecific
ssDNAindiscriminate 
ssDNase activity
PAM
unspecific
ssDNA
cleaved
new crRNA molecules 
displace cleaved R-loop 
and reset endonuclease activity
Fig. 3 Model mapping the catalytic pathway of CRISPR-Cas12a.
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and only when all three checkpoints are able to recognize the
hybrid, the enzyme is in a conformation competent for
catalysis. The endonuclease produces a staggered cut on a
PAM distal site on the DNA with a 5 nt overhang on the target
strand [31,36], and the PAMdistal end of the cleaved product is
then released from the complex [39].
Cleavage in the t-strand of the DNA by Cas12a produces a
50-phosphorylated product [35]. In order for both DNA strands
to be cut, theymust enter the catalytic sitewith a 50-30 polarity.
Structural studies reveal that the NTS is positioned to enter
the RuvC-Nuc pocket with the 50-30 polarity, while the TS has
the reverse polarity. An smFRET analysis suggests that Cas12a
has to undergo conformational changes in the distal part of
the REC and NUC lobes in order to allow the TS enter the
nuclease site with the correct polarity [36]. This could explain
why the NTS appears to be hydrolyzed faster than the TS.
Therefore, the cleavage of the NTS is a consequence of theproper positioning of this strand in the RuvC-Nuc catalytic
pocket rather than a requirement to initiate the cleavage re-
action. After both strands have been cleaved, the PAM distal
end of the cleavage product dissociates from the complex, but
the PAM proximal site remains associated to Cas12a forming a
cleaved R-loop [24,39].Indiscriminate ssDNA cleavage
Besides high-specific dsDNA cleavage, Cas12a has also been
shown to exhibit indiscriminate ssDNA degradation activity
upon activation with a ssDNA complementary to the crRNA
guide. This activity is displayed by all Cas12a orthologs and
degrades any available ssDNA molecule into single/double
nucleotides [40]. Comparisons of the structures of Cas12a
before, during and after cleavage reveal the structural
changes that result in such an indiscriminate activity. The
b i om e d i c a l j o u rn a l 4 3 ( 2 0 2 0 ) 8e1 7 13lid region, which is involved in the checkpoints for accurate
target recognition [36] is responsible for this action. Before
the crRNA-DNA hybrid is formed, the lid occludes the cleft
where the catalytic residues reside. Upon formation of the
hybrid, the lid changes conformation to form an a helix, thus
interacting with the crRNA of the hybrid assembly, thus
dissociating the polar interactions and making available the
catalytic pocket. In the R-loop structure after cleavage [24],
this region appears disordered indicating that the catalytic
site is accessible after the distal part of the dsDNA substrate
dissociates from the complex. Therefore, the catalytic cleft is
open and able to sever ssDNA indiscriminately. This mo-
lecular mechanism would explain how ssDNA molecules are
degraded by Cas12a after being activated by the presence of
the RNA-DNA hybrid [24,35,36]. In addition, recent studies
have reported non-specific nicking of target sequences
bearing mismatches in distal regions of the target DNA [41],
suggesting that this could be a problem for potential
applications.Cas12a endonuclease recycling
Unspecific ssDNA degradation presents a potential harmful
situation for the host cell since it could hinder basic cellular
processes such as replication, transcription and DNA repair.
This poses an important question: how could we eliminate
this harmful indiscriminate activity? As the cell cannot allow
an indiscriminate ssDNA degradation unleashed. The answer
to these problems can be found in the bacterial genomes
encoding Cas12a. Use of a conserved sequence of the crRNA
for a database search disclosed that different bacteria encode
a single copy of the Cas12a gene, whereas they encode mul-
tiple copies (up to 68) of the crRNA [18]. If the transcription
rates are presumed to be similar, at any given time, the con-
centration of various crRNAs in the cell would be multiple
times higher than that of the enzyme. It has been experi-
mentally shown that with sufficient concentration of a new
crRNA molecule, it is able to displace the cleaved R-loop from
the enzyme, with the help of accessory host proteins, forming
a new interference complex (Fig. 3). This shows that Cas12a
can revert the active conformation to shut down unspecific
activity by displacing the cleaved R-loop with a new crRNA. In
doing so, it reverts back to a conformation where the molec-
ular ‘lid’ forms polar interactions again to make the catalytic
pocket inaccessible [36]. By doing so, not only does the endo-
nuclease shut down the indiscriminate ssDNase activity, but
also recycles its catalytic activity towards other target DNAs.Cas12a vs Cas9
Cas12a and Cas9 have striking functional similarities despite
having evolved through independent pathways (Figs. 2 and 4),
with similar sizes (1368 amino acids for SpCas9; 1307 for
FnCas12a). They are both multidomain effector proteins and
adopt a bilobed architecture when in complex with their
respective RNAs. Cas9 requires two RNA molecules: tracrRNA
and a crRNA, whereas Cas12a requires only a single RNA
molecule, the crRNA. Cas9 possesses two nuclease sites HNHand RuvC domains, while Cas12a possesses only one nuclease
site in the RuvC domain. Additionally, Cas12a also possesses
an RNA processing site [1,9,24,31,34,37]. There are distinct
differences in the mechanisms employed by the two proteins
when it comes to RNA processing, PAM recognition, target
DNA binding and eventually catalysis.
After the CRISPR array has been transcribed into a long pre-
crRNA molecule, it is processed into mature crRNAs before it
can form an RNP with the endonuclease. In the case of Cas9,
the tracrRNA (encoded close to the CRISPR locus) first needs to
hybridize with the pre-crRNA, and then this hybrid RNAeRNA
duplex structure is recognized by Cas9, following which the
host RNase III cleaves the duplex, leaving a ~75 nt long
tracrRNA and a 39-42 nt long crRNA, which then forms the
RNP complex responsible for recognizing and degrading the
target DNA [33,42,43]. In contrast, Cas12a does not require a
tracrRNA or RNase III, since the protein processes its own
crRNA in its ribonuclease catalytic site [44]. In type-V CRISPR
locus of F. novicida, the spacers are 27e32bp sequences inter-
spersed by 36bp repeat sequences in between the spacers. In
the entire CRISPR array transcript, which is the pre-crRNA, the
repeat derived sequences form pseudoknots, which are
recognized by Cas12a. Following the recognition, the pre-
crRNA is cleaved forming ~43 nt mature crRNA
[25,26,31,34,35,45]. Logistically, Cas12a presents a more mini-
malistic system than Cas9.
For Cas9 targeted DNA sequences, the PAM is situated
downstream of the spacer sequence on the non-template
strand, and is recognized by the PI domain, which is primed
for identifying a 50-NGG-30 PAM [43,46]. In contrast, Cas12a
recognizes A-T rich sequences, with the PAM, typically 50-
TTTV-30, located upstream of the spacer. Upon PAM recogni-
tion, the target DNA is unzipped and hybridization of the RNA-
DNA takes place. For both enzymes exists a crucial seed
sequence next to the PAM to determine the specificity of target
DNA binding. The seed sequence for Cas9 is about ~10 nt
whereas for Cas12a it is about ~5e6 nt [9,31,34,35]. When the
hybridization of the DNA with the RNA is complete, Cas9
cleaves the template strand and the non-template strands in
the catalytic sites located in the HNH and the RuvC domains
respectively, producing a blunt DSB, with the cleavage site
being 3 base pairs upstream from the PAM sequence [9].
However, in the case of Cas12a due to the presence of a single
nuclease site, the strands of the DNA are cut in the same
nuclease site. Since it has been shown that the two strands
follow different pathways to reach the catalytic site, explain-
ing the staggered DSB produced by Cas12a [24,31].
Cleavage fidelity is an important issue for many of the
nucleases used in genome editing applications [47]. An
optimal tool must introduce modifications just on the target
site, leaving the rest of the genome unmodified in order to
avoid undesired changes in other sites of the genome with
unpredictable consequences. Therefore, specificity and the
resulting cleavage products are key in genome modification
applications. A recent comparison of different Cas12a and
Cas9 from different species using nuclease digestion and deep
sequencing (NucleaSeq) in vitro, revealed that both enzymes
share similar types of specificities and tolerate similar mis-
matches [48], in contrast to in vivo reports that show the lower
off-target effects of Cas12a [49,50]. This apparent
Cas9Cas12a
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Fig. 4 Cas12a vs Cas9.
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cleavage kinetics, but also to a possible different behaviour of
these cutters on a chromatin context, thus posing the ques-
tion whether in vitro or in vivo approaches should be pursued
for nuclease redesign efforts.CRISPR-Cas12a mediated genome editing
Application of CRISPR-Cas systems as molecular tools for
genome editing exploits their ability to produce a double
strand break (DSB) at a specific genomic locus, and depends
entirely on the host cell DNA repairmachinery to fix the lesion
produced by these systems. The repair mechanisms can be
either of the following processes: homology-directed repair
(HDR) or non-homologous end joining (NHEJ). HDR utilizes a
template DNA that is homologous to the break site (an un-
broken sister chromatid or a homologous chromosome) to
repair the DSB, whereas NHEJ is based on direct joining of
broken ends of the DSB, making NHEJ the more error prone
mechanism of the two. HDR can thus be used to supply
exogenous template DNA to implement a user defined change
in the host genome. NHEJ can be applied for gene disruptionwhereas HDR allows for the scope of introducing new genetic
information or direct correction of the sequence at a specific
locus.
At the center of CRISPR mediated genome engineering
today is Cas9, with applications including, but not limited to,
gene knockout and precise genome editing. Despite the rapid
advances in genomeediting by Cas9, it still presents challenges
owing to the possibility of off-target effects and difficulty of
delivering the ribonucleoprotein particle [18]. Cas12a, owing to
its substantial differences with Cas9, presents an alternate
molecular genome editing tool. The use of Cas12a in genome
editing for various cell types has been probed in several studies
up to date. Comparative studies of gene repression by cata-
lytically dead Cas9 from S. pyogenes (SpdCas9) and catalytically
dead Cas12a from Eubacterium eligens (EedCas12a) revealed that
the latter displays a higher gene repression in the template
strand of the target DNA than SpdCas9 [51]. It was also shown
that the pre-crRNA processing activity of Cas12a makes it an
attractive candidate for multiplex gene regulation, which is
cumbersome when attempted with Cas9 [52]. This auto-
processing of its own crRNA has been used to modify multi-
ple genetic elements simultaneously generating constitutive,
conditional, inducible, orthogonal and multiplexed genome
b i om e d i c a l j o u rn a l 4 3 ( 2 0 2 0 ) 8e1 7 15engineering of endogenous targets using multiple CRISPR
RNAs delivered on a single plasmid [53].
The viability of this approach has been further established
by other studies, in which multiplex gene regulation by
Cas12a was successfully observed in bacteria, plants, as well
as in mammalian cells [52,54e56]. Cas12a can also serve as a
solution in cell types where use of Cas9 is toxic, such as in
some industrial strains of Streptomyces [54].
Targeted mutagenesis in plants can also be achieved
through co-expression of Cas12a and its cognate crRNA
in vivo, as was shown in rice. Additionally, it was also
shown that the mutagenesis was more efficient through the
use of pre-crRNAs with full-length direct repeat sequences
than with mature crRNAs [57]. Efficient mutagenesis
through delivery of the pre-assembled ribonucleoprotein
(RNP) particle was also observed in soybean and wild to-
bacco. The RNP was assembled from recombinantly
expressed Cas12a and in vitro transcribed or chemically
synthesized crRNAs [58].
Successful gene editing of mammalian cells using Cas12a
include correction of mutations causing Duchennemuscular
dystrophy (DMD) in patient derived induced pluripotent
stem cells (iPSCs) and in mdx mice, a popular model for
studying DMD. Dystrophin expression was reinstated in
iPSCs after Cas12a-mediated gene editing, while in the mdx
mice, corrections in the pathophysiological hallmarks of
muscular dystrophy were observed [59]. Delivery of the
adenovirus vector with an AsCas12a expression cassette
yielded successful mutations in primary human hepatocytes
from humanized mice with chimeric liver [60]. Cas12a-
mediated genome editing was also used to engineer rat
models that mimic human atherosclerosis and this system
may have potential applications in understanding early
stage atherosclerosis [61].
All of the above studies how Cas12a can be engineered for
various applications. Despite the numerous recent advances
in the application of Cas12a, there remain vast avenues of
unexplored potential of Cas12a in terms of therapeutics and
diagnostics.Cas12a applications in bioengineering
Currently, a vast effort is ongoing to redesign all these tools for
biomedical and biotechnological applications. However,
recent studies have envisioned the possibility of using
CRISPR-Cas nucleases in bioengineering of smart materials,
for example hydrogels [62] These water-filled polymers are
encapsulated by DNA. In a recent study, Cas12a has been used
to specifically degrade the DNA scaffold of DNA hydrogels,
thus opening the possibility that this smart cutter can be
turned into a programmable device to deliver the cargo of DNA
encaged hydrogels in a determined location at a certain time.
The cleavage properties of Cas12a make it an ideal candidate
to promote controlled delivery of the cargo. Although, appli-
cation of these approaches and their combinations can be
now envisioned by many researchers, the range of possibil-
ities in different areas is so large that it is beyond our
imagination.Conclusions
In this review we have sought to offer a condensed overview
of the functionality of CRISPR-Cas12a, discussing the struc-
tural and functional features of the different stages of the
reaction pathway leading up to the catalysis of the target DNA,
and eventually discussing the applications of Cas12a in brief.
Cas12a employs a multi-checkpoint mechanism to ensure
precise targeting of DNA, which is a desirable property in a
genome editing tool in order to have low off target effects.
Although it has been shown that the indiscriminate ssDNA
degradation of Cas12a could be shut down through the
recruitment of a new crRNAmolecule, it could still potentially
harm the host cell targeted for genome modification. Modu-
lation of this activity is necessary to achieve higher regulation
and control of Cas12a catalysis, and in turn to achieve a more
robust genome editing tool. In this direction structural infor-
mation has been used to redesign Cas12a obtaining variants
without ssDNA unspecific activity, thus severing only dsDNA
specifically [36].
Currently, Cas9 and Cas12a, are the sole members of the
CRISPR family that have been utilized for genome editing.
Owing to their significant similarities and differences, just
these two endonucleases between themselves have made the
applications of CRISPR highly versatile. Cas12a, in some cases,
offers certain advantages over Cas9, for example in its capa-
bility to be used for multiplex genome editing and production
of staggered DSB, which promotes HDR instead of NHEJ. Sig-
nificant research also is ongoing to engineer artificial variants
of Cas9 and Cas12a to recognize different PAM than the wild
type proteins, which will facilitate the targeting of a wider li-
brary of genomes.
The rapid advent of the CRISPR-Cas technology for
genome manipulation has been revolutionary for life sci-
ences. Despite the vast application areas of this technology,
the current state of the art of the CRISPR molecular tools
(Cas9 or Cas12a) suffers from one important drawback:
dependence on host cell DNA repair machinery. Both Cas9
and Cas12a based technology produce a double strand break
(DSB) in the target DNA, and this break is then repaired by
endogenous DNA repair machinery with or without the
presence of a template. Although these tools have been
successfully utilized to obtain precise insertion of DNA into
the targeted genomic loci, their efficiency differs from cell
type to cell type [63e65]. DNA repair through HDR is also
related to active cell division, which makes these tools
ineffective in cell types that are not actively dividing, such
as neurons. Recent studies characterizing CRISPR-
associated transposase (CAST), which comprises Tn7-like
transposase subunits and a CRISPR effector from type
VeK, could pave the way to new avenues of gene editing
using CRISPR systems since these systems are self-sufficient
in precise DNA insertion and do not depend on endogenous
cell DNA repair machinery [66,67]. However, a large ongoing
research is aiming to tailor both Cas9 and Cas12a further to
ensure precise DNA insertion into the targeted genome.
Even apart from this apparent drawback, both these tools
have a vast range of applicability and ongoing efforts are
b i om e d i c a l j o u r n a l 4 3 ( 2 0 2 0 ) 8e1 716striving to produce improved and more robust engineered
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